OrbiMed Advisors LLC
- SEC CIK
- 0001055951
- Latest filing
- Aug 14, 2026
PASG holding history
Passage BIO, Inc. in every 13F filed by OrbiMed Advisors LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
PASG overviewAll 13F holders of PASGFull Q2 2026 holdings
- Shares (Q4 2025)
- 0
- Sold out in Q4 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 19
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2025 | 0 | $0 | 0.0% | −59,046−100.0% | Sold out | Holders |
| Q3 2025 | 59,046 | $474.1K | <0.1% | −243,719−80.5% | ReducedConverted for a 1-for-20 split | Holders |
| Q2 2025 | 6,055,300 | $2.42M | 0.1% | −979,326−13.9% | Reduced | Holders |
| Q1 2025 | 7,034,626 | $2.48M | 0.1% | −370,243−5.0% | Reduced | Holders |
| Q4 2024 | 7,404,869 | $4.20M | 0.1% | −2,418,007−24.6% | Reduced | Holders |
| Q3 2024 | 9,822,876 | $6.88M | 0.1% | −301,700−3.0% | Reduced | Holders |
| Q2 2024 | 10,124,576 | $8.04M | 0.2% | 00.0% | Unchanged | Holders |
| Q1 2024 | 10,124,576 | $13.7M | 0.3% | 00.0% | Unchanged | Holders |
| Q4 2023 | 10,124,576 | $10.2M | 0.2% | 00.0% | Unchanged | Holders |
| Q3 2023 | 10,124,576 | $6.66M | 0.2% | 00.0% | Unchanged | Holders |
| Q2 2023 | 10,124,576 | $9.53M | 0.2% | +1,192,577+13.4% | Added | Holders |
| Q1 2023 | 8,931,999 | $8.55M | 0.2% | 00.0% | Unchanged | Holders |
| Q4 2022 | 8,931,999 | $12.3M | 0.2% | 00.0% | Unchanged | Holders |
| Q3 2022 | 8,931,999 | $11.2M | 0.2% | 00.0% | Unchanged | Holders |
| Q2 2022 | 8,931,999 | $21.1M | 0.4% | +1,600,000+21.8% | Added | Holders |
| Q1 2022 | 7,331,999 | $22.7M | 0.4% | +369,100+5.3% | Added | Holders |
| Q4 2021 | 6,962,899 | $44.2M | 0.6% | 00.0% | Unchanged | Holders |
| Q3 2021 | 6,962,899 | $69.3M | 0.8% | 00.0% | Unchanged | Holders |
| Q2 2021 | 6,962,899 | $92.2M | 0.9% | 00.0% | Unchanged | Holders |
| Q1 2021 | 6,962,899 | $121.7M | 1.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.